Efficacy , safety , and prognostic indicators of first ‐ line sunitinib in patients with metastatic renal cell carcinoma : A single center experience


Background: We assessed the efficacy and safety of sunitinib as the first‐line treatment in metastatic renal cell carcinoma (mRCC) patients. The predictors of survival and efficacy in mRCC as identified from previous studies, including the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic RCC Database Consortium (IMDC) factors… (More)

6 Figures and Tables


  • Presentations referencing similar topics